Penn Pharma and Xcelience, LLC have entered into a joint venture agreement to provide Capsugel’s Xcelodose precision powder micro-dosing system technology on a global basis. Xcelodose is a registered trademark of Capsugel, a division of Pfizer.
The JV aims to provide pharma and biopharma companies with the opportunity to manufacture first in human batches faster and closer to clinical sites. The companies will operate on the network of Xcelodose systems worldwide, which is designed to guarantee immediate manufacturing capacity.
“This joint venture will create a powerful partnership between two leading providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance,” said Derek Hennecke, chief executive officer and president of Xcelience. “Xcelience has more than six years experience in powder in capsule technology and has processed more than 100 clinical supply batches using the Xcelodose technology,” notes Paul Wituschek, Global Sales & Marketing Director of Penn. “Penn will be able to immediately leverage this expertise to provide this important accelerated development option to our clients.”